Phathom Pharmaceuticals Faces Investor Probe After Lowering Revenue Targets

Florham Park, Tuesday, 4 August 2026.
Phathom Pharmaceuticals is facing shareholder law investigations after cutting its 2026 revenue forecast to $310–325 million, sparking a 22% stock selloff and allegations of misleading investors.